PhRMA Code on Interactions - Annual Certifications

PhRMA Code on Interactions - Signatory Companies

Dementia Report Wake-up Call

04.04.13 | By

If you're not worried by dementia - its personal cost and its economic toll - you should be. I am. Anyone who, like me, has had a family member die with dementia understands the devastation: the years - if not decades - of the living loss of a loved one; the drain on family and healthcare resources; the unmet hope that something may be done to relieve or reverse the insidious progress of the condition.

Incremental Innovation Series: Focus on Rheumatoid Arthritis

04.03.13 | By

As part of our ongoing incremental innovation series on the Catalyst, Thomas F. Goss, PharmD, Senior Vice President, Boston Healthcare Associates, highlights the importance of medical progress for patients suffering from rheumatoid arthritis in his very own blog post: The weather is warming (finally) here in the northeast, and like many families, we found ourselves enjoying the warm outdoor weather this past weekend.

Incremental Innovation Series: Lilly Weighs In...

04.02.13 | By

David Grainger, Global Public Policy Director, Eli Lilly and Company, is sharing with us a blog post he wrote about the value of innovative treatments for cancer, Health Technology Assessment and the overall theme of incremental innovation - which is a focus this week on the Catalyst:

Countdown to #PhRMA13

04.02.13 | By

Next week, we will convene leaders from the biopharmaceutical industry, the patient community, academia and beyond to discuss how we can all work together to advance research, progress and hope for the millions of patients who rely on innovative medicines.

Defining Innovation

04.01.13 | By

We talk a lot about innovation in health care. This week on the Catalyst we’d like to take a step back and look at the big picture. What is innovation? How does it come about? How is biomedical innovation contributing to progress against serious and life-threatening diseases and conditions?

PhRMA Statement on India Supreme Court Decision on Glivec

WASHINGTON, D.C. (April 1, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani issued the following statement today:

Week in Review: Recognizing the Value of New Medicines

03.29.13 | By

This week, many of our Catalyst posts explored the value of medicinal development and its ability to improve the lives of patients. Although moving new drugs through the rigorous approval process is expensive and time consuming, several major triumphs for scientists and clinicians recently verified the value of investing in innovative research and development, citing the long-term human and economic benefits.

New Medicines Offer Benefits

03.29.13 | By

As I skim the new report “Medicines in Development for Older Americans,” I’m reminded how new medications that are still being developed and clinically tested have already begun to have positive impacts on patients and local economies all over the country.

Pages

Subscribe to RSS - Opinion